ChemicalBook >> journal list >> STAR Protocols >>article
STAR Protocols

STAR Protocols

IF: 1.3
Download PDF

Optimization of antigen-specific CD8+ T cell activation conditions for infectious diseases including COVID-19

Published:17 September 2021 DOI: 10.1016/j.xpro.2021.100789 PMID: 34414379
Chanchan Xiao, Congling Qiu, Jieping Deng, Jiezhou Ye, Lijuan Gao, Jun Su, Oscar Junhong Luo, Pengcheng Wang, Guobing Chen

Abstract

Here, we describe the use of the artificial antigen-presenting cell (aAPC) system for the verification of T-cell epitopes. We purify and activate CD8+ T cells from blood samples from HLA-A2 that are negative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). CD8+ T cells are combined with peptide-loaded T2-A2 cells, which are then stained with a SARS-CoV-2-specific MHC-1 tetramer to identify specific HLA-A2-restricted T-cell epitopes. The use of aAPC and healthy donors means that only BSL2 lab conditions are needed. For details of the use and implementation of this protocol, please refer to Deng et al. (2021).

Substances (6)

Materials Related products
Procduct Name CAS Molecular Formula Supplier Price
5(6)-(N-SUCCINIMIDYLOXYCARBONYL)-3',6',O,O'-DIACETYLFLUORESCEIN 150347-59-4 C29H19NO11 232 suppliers $70.00-$2200.00
5(6)-(N-SUCCINIMIDYLOXYCARBONYL)-3',6',O,O'-DIACETYLFLUORESCEIN 150347-59-4 C29H19NO11 232 suppliers $70.00-$2200.00
5(6)-(N-SUCCINIMIDYLOXYCARBONYL)-3',6',O,O'-DIACETYLFLUORESCEIN 150347-59-4 C29H19NO11 232 suppliers $70.00-$2200.00
5(6)-(N-SUCCINIMIDYLOXYCARBONYL)-3',6',O,O'-DIACETYLFLUORESCEIN 150347-59-4 C29H19NO11 232 suppliers $70.00-$2200.00

Similar articles

IF:4.2

Dexamethasone: Therapeutic potential, risks, and future projection during COVID-19 pandemic

European journal of pharmacology Sobia Noreen, Irsah Maqbool,etc Published: 5 March 2021
IF:4.7

Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19.

Infectious Diseases and Therapy Takahiro Takazono, Satoki Fujita,etc Published: 1 August 2024
IF:7.6

Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial

The Lancet Regional Health: Western Pacific Fuxiang Wang , Wen Xiao ,etc Published: 1 September 2023